Dimebon attenuates methamphetamine, but not MPTP, striatal dopamine depletion

详细信息	查看全文 | 推荐本文 |

• 作者：Werner J. Geldenhuys^a ; Altaf S. Darvesh^a ; Dean E. Dluzen^a ; ^b ; ^{ded@meomed.edu}
• 关键词：ANOVA ; analysis of variance ; CNS ; central nervous system ; DA ; Dopamine ; HPLC ; high pressure liquid chromatography ; MA ; methamphetamine ; MDMA ; methylenedioxymethamphetamine ; MPTP ; 1-methyl-4-phenyl-1 ; 2 ; 3 ; 6-tetrahydropyridine ; MPP+ ; 1-methyl-4-phenylpyridin
• 刊名：Neurochemistry International
• 出版年：2012
• 期刊代码：120_01970186
• 类别：bio
• 出版时间：June, 2012
• 卷：60
• 期：8
• 页码：806-808
• 文件大小：190 K

摘要

Dimebon is an anti-histamine with central nervous system activity. In this report the effects of dimebon as a neuroprotectant in animal models of Parkinson鈥檚 disease were tested as assessed in methamphetamine- and MPTP-induced striatal dopaminergic toxicity. Dimebon (1 mg/kg) administered at 30 min prior to methamphetamine (40 mg/kg) significantly reduced the amount of striatal dopamine depletion in mice, without altering the initial methamphetamine-induced increase in body temperature. In contrast, dimebon at either 1 or 25 mg/kg administered at 30 min prior to MPTP (35 mg/kg) was unable to prevent MPTP-induced striatal dopamine loss as determined at 7 days post-methamphetamine/MPTP. These data suggest that dimebon may be exerting a neurotoxin specific neuroprotective effect upon the striatal dopaminergic system and may serve as an important tool for discriminating the mechanistic basis of these two dopaminergic neurotoxins.